Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis

NANot yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Diabetic Nephropathies
Interventions
DRUG

Henagliflozin

On the basis of hypoglycemic therapy, the patients in the intervention group were given the drug treatment of hengglinide, once a day, 10mg or 5mg each time, taken in the morning, for 12 months.

DRUG

Placebo

On the basis of basic treatment, patients in the blank control group were given starch tablets once a day, 10mg or 5mg each time, taken in the morning for 12 months.

All Listed Sponsors
lead

Qianfoshan Hospital

OTHER

NCT06031389 - Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis | Biotech Hunter | Biotech Hunter